Evox Therapeutics acquires exosome AAV technology and IP

Oxford University, UK, biotech spinout Evox Therapeutics has purchased USA-base Codiak Biosciences’ engEx-AAV technology platform, including all intellectual property rights therein, as well as secured exclusive access to certain associated engineering and manufacturing rights.

Evox says this technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralizing antibodies.

Financial terms of the transaction were not disclosed.